Cerebrospinal fluid inflammatory biomarkers predicting interferon-beta response in MS patients.

ABSTRACT:

Background and aims

Interferon beta (IFNb) is a safe first-line drug commonly used for relapsing-remitting (RR)-MS. Nevertheless, a considerable proportion of patients do not respond to IFNb treatment. Therefore, until now, a number of studies have investigated various markers that could predict the patients who would respond to IFNb therapy. The objective of this study was to identify reliable biomarkers to predict the efficacy of IFNb treatment in MS.

Methods

In a group of 116 patients with clinically isolated syndrome (CIS) and RR-MS, we explored the association between CSF detectability of a large set of proinflammatory and anti-inflammatory molecules at the time of diagnosis and response to IFNb after the first year of treatment. The absence of clinical relapses, radiol

SUBMITTER: Stampanoni Bassi M 

PROVIDER: S-EPMC7727083 | biostudies-literature | 2020

REPOSITORIES: biostudies-literature